메뉴 건너뛰기




Volumn 23, Issue 3, 2009, Pages 429-431

Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENFUVIRTIDE; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

EID: 59949106038     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283229f81     Document Type: Article
Times cited : (11)

References (7)
  • 1
    • 33748452016 scopus 로고    scopus 로고
    • UNAIDS/WHO, December
    • UNAIDS/WHO. AIDS Epidemic Update. December 2006.
    • (2006) AIDS Epidemic Update
  • 2
    • 59949102312 scopus 로고    scopus 로고
    • UNAlDS/UNFPA/UNIFEM. Women and HIV/AIDS: Confronting the Crisis. 2004.
    • UNAlDS/UNFPA/UNIFEM. Women and HIV/AIDS: Confronting the Crisis. 2004.
  • 5
    • 33746576313 scopus 로고    scopus 로고
    • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug resistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials
    • Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials, Lancet 2006; 368:466-475.
    • (2006) Lancet , vol.368 , pp. 466-475
    • Hicks, C.B.1    Cahn, P.2    Cooper, D.A.3    Walmsley, S.L.4    Katlama, C.5    Clotet, B.6
  • 6
    • 34247358210 scopus 로고    scopus 로고
    • Tipranavir/r demonstrates superior and durable treatment response compared with comparator protease inhibitor/r in highly treatment experienced patients: Week 96 RESIST 1 and 2 results
    • San Francisco, California, USA;
    • Farthing C, Ward D, Hicks C, Johnson M, Cauda R, Cahn P. Tipranavir/r demonstrates superior and durable treatment response compared with comparator protease inhibitor/r in highly treatment experienced patients: week 96 RESIST 1 and 2 results. 46th annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, USA; 2006.
    • (2006) 46th annual Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Farthing, C.1    Ward, D.2    Hicks, C.3    Johnson, M.4    Cauda, R.5    Cahn, P.6
  • 7
    • 38749089966 scopus 로고    scopus 로고
    • Tipranavir/r (TPV/r) maintains long term virological suppression - week 156 results of RESIST
    • Madrid, Spain;
    • Hicks C, Cahn P, Jelaska A, Drulak M, Vinisko R. Tipranavir/r (TPV/r) maintains long term virological suppression - week 156 results of RESIST. 11th European AIDS Conference. Madrid, Spain; 2007.
    • (2007) 11th European AIDS Conference
    • Hicks, C.1    Cahn, P.2    Jelaska, A.3    Drulak, M.4    Vinisko, R.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.